Profile Response Detail

Molecular Profile Unknown unknown
Therapy DHA + Regorafenib
Indication/Tumor Type kidney cancer
Response Type not applicable
Create By tyin
Update By cstatz


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown kidney cancer not applicable DHA + Regorafenib Preclinical - Cell line xenograft Actionable In a preclinical study, DHA and Stivarga (regorafenib) synergistically inhibited survival of kidney cancer cells in culture and reduced tumor growth in kidney cancer cell line xenograft models (PMID: 26921392). 26921392
PubMed Id Reference Title Details
(26921392) Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy. Full reference...